News & Events
Biopharmaceutical Company of the Year
Ventoux Biosciences Recognized as Biopharmaceutical Company of the Year We are honored and excited to share that Ventoux Biosciences has received the award for Biopharmaceutical
Biosciences Innovator Launches Fundraising Round After Successful Pre-Clinical Results for Fibrosis Treatment
Dupuytren’s is a common, progressive, debilitating fibrosis of the hands. Ventoux Biosciences is on a mission to develop new treatment options.
A founder’s quest for a drug to treat his own hand condition kicks off with positive mouse data
The surgeons who treat it call it “the most common crippling hand disease you’ve never heard of”: Dupuytren’s contracture, an incurable, sometimes painful disorder where cords of fibrotic
Ventoux Biosciences Announces Positive Pre-Clinical Results, Initiates Fundraising Round to Advance Development
Ventoux Biosciences, Founded by Dupuytren’s Patient, Announces Positive Anti-Fibrotic Effects with VEN-201 and Initiates Initial Fundraising Round ENCINITAS, CALIFORNIA, UNITED STATES, March 12, 2024 /EINPresswire.com/
Hands of Change Podcast
Hands of Change is a new podcast dedicated to Dupuytren’s disease and related conditions. Hosted by Kurt Harrington and supported by Ventoux Biosciences, the show
Ventoux Biosciences Appoints Dr. Ken Lipson, PhD as Chief Scientific Officer
San Diego, December 26, 2023 — Ventoux Biosciences, a trailblazing specialty pharmaceutical company dedicated to developing groundbreaking, first-line therapies for Dupuytren’s disease, proudly welcomes Dr.